In a new study funded by Pro Generika, a German pharmaceutical lobbying group, researchers determined that, as of Apr 30, 2020, 63% of the country's commonly used generic active pharmaceutical ingredients (APIs) came from Asia and 33% from Europe—almost a complete inverse compared with 20 years ago.Findings of the report may hold lessons for US manufacturers, policymakers, and preparedness experts, especially in light of COVID-19, because the American market has similar shortcomings.The researchers, from MundiCare Life Science Strategies, looked at the CEPs (or certificate of suitability of monographs of the European Pharmacopoeia) of 565 generic APIs needed for German patient care to determine the location of their manufacturing sites.CEPs